Home > Protocol Summaries: Compounds > SB742457 Protocol Summaries: SB742457 GSKStudy ID Phase Title Status AZ3100603 Phase 2 A phase IIa/b double-blind, randomised, placebo-controlled, linear trend design dose-ranging study to investigate the effects of 24 weeks of monotherapy with SB-742457 on cognition in subjects with mild to moderate Alzheimer's disease Completed AZ3106242 Phase 2 A Double-Blind, Randomised, Placebo-Controlled, Parallel Group Study to Investigate the Effects of SB-742457, Donepezil and Placebo on Cognition in Subjects with Mild to Moderate Alzheimer’s Disease Completed AZ3110291 Phase 1 An open-label, randomised, two-part crossover study to assess the pharmacokinetics of a single dose of SB-742457 formulated as a capsule and a tablet in healthy elderly volunteers. Completed AZ3110865 phase 2 Study AZ3110865, a study comparing SB-742457 or donepezil versus placebo in subjects with mild-to-moderate Alzheimer’s disease Completed AZ3110866 phase 2 Study AZ3110866, a fixed dose study of SB-742457 versus placebo when added to existing donepezil treatment in subjects with mild-to-moderate Alzheimer’s disease Completed
